%0 Journal Article
%T Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy.
%A Dheeraj A
%A Garcia Marques FJ
%A Tailor D
%A Bermudez A
%A Resendez A
%A Pandrala M
%A Grau B
%A Kumar P
%A Haley CB
%A Honkala A
%A Kujur P
%A Jeffrey SS
%A Pitteri S
%A Malhotra SV
%J Cell Rep Med
%V 5
%N 5
%D 2024 May 21
%M 38729158
%F 16.988
%R 10.1016/j.xcrm.2024.101552
%X Y-box binding protein-1 (YB-1) is a proto-oncogenic protein associated with protein translation regulation. It plays a crucial role in the development and progression of triple-negative breast cancer (TNBC). In this study, we describe a promising approach to inhibit YB-1 using SU056, a small-molecule inhibitor. SU056 physically interacts with YB-1 and reduces its expression, which helps to restrain the progression of TNBC. Proteome profiling analysis indicates that the inhibition of YB-1 by SU056 can alter the proteins that regulate protein translation, an essential process for cancer cell growth. Preclinical studies on human cells, mice, and patient-derived xenograft tumor models show the effectiveness of SU056. Moreover, toxicological studies have shown that SU056 treatment and dosing are well tolerated without any adverse effects. Overall, our study provides a strong foundation for the further development of SU056 as a potential treatment option for patients with TNBC by targeting YB-1.